

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Lysine-specific histone demethylase 1 (KDM1A; LSD1)	<p>A study in cell culture identified urea- and thiourea-based LSD1 inhibitors that could help treat cancer. In a human lung carcinoma cell line, 10 <math>\mu</math>M of an inhibitor increased histone methylation and expression of an LSD1 target gene and decreased cell viability compared with no treatment. Next steps include evaluating the specificity of the compounds for LSD1 and investigating their effects on the expression of tumor suppressor genes.</p> <p>PG11144, an LSD1 inhibitor from Progen Pharmaceuticals Ltd., is in preclinical development for cancer.</p> <p><b>SciBX 3(28); doi:10.1038/scibx.2010.855</b>  <b>Published online July 22, 2010</b></p>	Provisional patent application filed covering compounds and their use as antitumor agents; available for licensing	<p>Sharma, S.K. <i>et al. J. Med. Chem.</i>; published online June 22, 2010; doi:10.1021/jm100217a</p> <p><b>Contact:</b> Patrick M. Woster, Wayne State University, Detroit, Mich.            e-mail: <a href="mailto:pwoster@wayne.edu">pwoster@wayne.edu</a></p>